EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dihydropyrimidone Derivatives as Thymidine Phosphorylase Inhibitors: Inhibition Kinetics, Cytotoxicity, and Molecular Docking

Tian-Meng Cui, Muhammad Altaf, Abdu Aldarhami iD, Abdulrahman S Bazaid iD, Nizar H Saeedi iD, Almohanad A Alkayyal iD, Fahad M Alshabrmi iD, Farman Ali, Mohammed Aladhadh, Muhammad Yasir Khan, Ahad Amer Alsaiari iD, Yue-Rong Ma

Molecules · 21.04.2023 · 28 (8) · 3634

DOI: 10.3390/molecules28083634 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 21.04.2023. Verfasst von Tian-Meng Cui und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China. Hauptthemen laut MEDLINE: Thymidine Phosphorylase, Enzyme Inhibitors. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research at Umm Al-Qura University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overexpression of the thymidine phosphorylase (TP) enzyme induces angiogenesis, which eventually leads to metastasis and tumor growth. The crucial role of TP in cancer development makes it an important target for anticancer drug discovery. Currently, there is only one US-FDA-approved drug, i.e., Lonsurf, a combination of trifluridine and tipiracil, for the treatment of metastatic colorectal cancer. Unfortunately, numerous adverse effects are associated with its use, such as myelosuppression, anemia, and neutropenia. Since the last few decades, the discovery of new, safe, and effective TP inhibitory agents has been rigorously pursued. In the present study, we evaluated a series of previously synthesized dihydropyrimidone derivatives 1–40 for their TP inhibitory potential. Compounds 1, 12, and 33 showed a good activity with IC50 = 314.0 ± 0.90, 303.5 ± 0.40, and 322.6 ± 1.60 µM, respectively. The results of mechanistic studies revealed that compounds 1, 12, and 33 were the non-competitive inhibitors. These compounds were also evaluated for cytotoxicity against 3T3 (mouse fibroblast) cells and were found to be non-cytotoxic. Finally, the molecular docking suggested the plausible mechanism of non-competitive inhibition of TP. The current study thus identifies some dihydropyrimidone derivatives as potential inhibitors of TP, which can be further optimized as leads for cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thymidine PhosphorylaseEnzyme InhibitorsAnimalsMiceMolecular Docking SimulationDrug Discovery

Stichwörter der Autor:innen

angiogenesisanti-cancerdihydropyrimidone derivativesmolecular dockingnon-competitive inhibitionthymidine phosphorylase (TP)

Substanzen

Thymidine PhosphorylaseEnzyme Inhibitors

Autor:innen und Institutionen

  • School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
  • Department of Biochemistry, Federal Urdu University of Arts, Sciences and Technology, Karachi 75300, Pakistan.
  • Department of Medical Microbiology, Qunfudah Faculty of Medicine, Umm Al-Qura University, Al-Qunfudah 21961, Saudi Arabia.
  • Department of Medical Laboratory Science, College of Applied Medical Sciences, University of Ha'il, Hail 55476, Saudi Arabia.
  • Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk 71491, Saudi Arabia.
  • Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia.

ORCID-Profile: Abdu Aldarhami, Abdulrahman S Bazaid, Nizar H Saeedi, Almohanad A Alkayyal, Fahad M Alshabrmi, Ahad Amer Alsaiari

Förderung

  • Deanship of Scientific Research at Umm Al-Qura University

Zitieren

APA

Cui, T. M., Altaf, M., Aldarhami, A., Bazaid, A. S., Saeedi, N. H., Alkayyal, A. A., Alshabrmi, F. M., Ali, F., Aladhadh, M., Khan, M. Y., Alsaiari, A. A., & Ma, Y. R. (2023). Dihydropyrimidone Derivatives as Thymidine Phosphorylase Inhibitors: Inhibition Kinetics, Cytotoxicity, and Molecular Docking. Molecules, 28(8), 3634. https://doi.org/10.3390/molecules28083634

Vancouver

Cui TM, Altaf M, Aldarhami A, Bazaid AS, Saeedi NH, Alkayyal AA, et al. Dihydropyrimidone Derivatives as Thymidine Phosphorylase Inhibitors: Inhibition Kinetics, Cytotoxicity, and Molecular Docking. Molecules. 2023;28(8):3634. doi:10.3390/molecules28083634

BibTeX
@article{Cui2023,
  author = {Cui, Tian-Meng and Altaf, Muhammad and Aldarhami, Abdu and Bazaid, Abdulrahman S and Saeedi, Nizar H and Alkayyal, Almohanad A and Alshabrmi, Fahad M and Ali, Farman and Aladhadh, Mohammed and Khan, Muhammad Yasir and Alsaiari, Ahad Amer and Ma, Yue-Rong},
  title = {Dihydropyrimidone Derivatives as Thymidine Phosphorylase Inhibitors: Inhibition Kinetics, Cytotoxicity, and Molecular Docking},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {8},
  pages = {3634},
  doi = {10.3390/molecules28083634}
}
Kostenlos starten →